Pharma Industry Reshapes Licensing Deals to Blunt MFN Drug Pricing

Legal Landscape and Regulatory Risk

The legal advisors quoted by industry publications emphasized that the restructuring strategies being contemplated are not evasion schemes — they operate within existing legal frameworks governing pharmaceutical licensing, intellectual property transfers, and multinational corporate structure. The challenge is that MFN pricing policy is itself still evolving, and the specific implementation rules that would determine how reference prices are calculated have not been fully codified.

This regulatory uncertainty cuts both ways. Companies that restructure now based on their best reading of where MFN rules are headed may find that final regulations are written differently, requiring further adaptation. Those that wait for regulatory certainty before acting may find themselves more constrained when rules are finalized.

Biosimilars and Generic Implications

MFN policy has different implications depending on whether a drug is a branded biologic, a small molecule pharmaceutical, or a biosimilar. For branded biologics — large, complex molecules that dominate the highest-cost segment of pharmaceutical spending — the price gaps between the US and other markets are often the largest, making MFN impact potential most acute. For these drugs, the licensing restructuring strategies are most actively being considered.

Biosimilars, which compete with branded biologics at reduced prices after patent expiration, present a different calculus. If MFN pricing reduces reference brand prices, the launch price point for biosimilars needs to adjust accordingly — a dynamic that could affect the competitive economics of biosimilar development and launch decisions.

Patient and Payer Perspectives

From the perspective of patients and payers who bear drug costs, any reduction in US pharmaceutical prices through MFN implementation would be welcome, and the industry's efforts to minimize that reduction through licensing structure changes will inevitably attract criticism as prioritizing shareholder value over patient access.

The pharmaceutical industry's counterargument — that sustained innovation depends on the revenue premium that US prices provide, and that MFN pricing would reduce capital available for early-stage research — is one that policy economists debate without reaching consensus. What is clear is that the MFN policy debate is shaping real business decisions now, well before any final implementation rules are in place, as companies attempt to position themselves for multiple regulatory scenarios simultaneously.

This article is based on reporting by endpoints.news. Read the original article.